Clinical meetings

← vista completa

Published on April 1, 2010 | http://doi.org/10.5867/medwave.2010.04.4497

Dyslipidemia in internal medicine

Dislipidemia en medicina interna

Rodolfo Lahsen M.

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Rodolfo Lahsen M.

Clínica Las Condes, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Lahsen M. R. Dyslipidemia in internal medicine. Medwave 2010;10(4):e4497 doi: 10.5867/medwave.2010.04.4497

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/04/2010

Index

Metrics

Not available at the moment.

Notes

Keywords

dislipidemia, metabolismo, endocrinología, medicina interna

References

  1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. | CrossRef | PubMed
  2. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004 Jun 2;43(11):2142-6. | PubMed
  3. Ministerio de Salud. Encuesta Nacional de Salud–MINSAL, 2004
  4. Araya I, Berríos A, Contreras C, Franulic L, Lahsen R. Diabetes tipo 2 en el adulto mayor: características clínicas y de laboratorio. En: XV Congreso SOCHEM, Concepción 2004.
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. | CrossRef | PubMed
  6. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005 Apr 11;165(7):725-30. | CrossRef | PubMed
  7. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am. 2000 Jan;84(1):23-42. | CrossRef | PubMed
  8. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229-34. | CrossRef | PubMed
  9. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 2006 Jul;152(1):27-38. | CrossRef | PubMed
  10. Reasner C. Rational therapy of mixed dyslipidaemia in a patient with diabetes. British Journal of Diabetes & Vascular Disease January 2007 vol. 7 no. 1 25-30. | CrossRef | Link
  11. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. | CrossRef | PubMed
  12. Schulte H, Cullen P, Assmann G. Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis. 1999 May;144(1):199-209. | CrossRef | PubMed
  13. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ. 1998 Mar 14;316(7134):823-8. | CrossRef | PubMed
  14. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006 May 13;332(7550):1115-24. Epub 2006 Apr 3. | CrossRef | PubMed
  15. Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care. 1998 Aug;21(8):1258-65. | CrossRef | PubMed
  16. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993 Jul;92(1):141-6. | CrossRef | PubMed
  17. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-9. | CrossRef | PubMed
  18. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541-9. | CrossRef | PubMed
  19. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004 Sep 9;351(11):1106-18. | CrossRef | PubMed
  20. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61. | CrossRef | PubMed
  21. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000 Dec 23-30;356(9248):2119-25. | CrossRef | PubMed